Statin wars: The heavyweight match-atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease

DiNicolantonio, James J., Lavie, Carl J., Serebruany, Victor L. and O'Keefe, James H. (2013) Statin wars: The heavyweight match-atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease. Postgraduate Medicine, 125 1: 7-16. doi:10.3810/pgm.2013.01.2620

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author DiNicolantonio, James J.
Lavie, Carl J.
Serebruany, Victor L.
O'Keefe, James H.
Title Statin wars: The heavyweight match-atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease
Journal name Postgraduate Medicine   Check publisher's open access policy
ISSN 0032-5481
1941-9260
Publication date 2013-01
Year available 2013
Sub-type Article (original research)
DOI 10.3810/pgm.2013.01.2620
Volume 125
Issue 1
Start page 7
End page 16
Total pages 10
Place of publication Berwyn, PA United States
Publisher J T E Multimedia, LLC
Collection year 2014
Language eng
Formatted abstract
Statins are a standard of care in many clinical settings, especially for dyslipidemia management, and are used for the primary and secondary prevention of cardiovascular disease. Importantly, not all statins are born equal. The statin class consists of a number of heterogenous drugs, which vary in properties such as potency in lowering low-density lipoprotein cholesterol levels, lipophilicity, renoprotection, increasing high-density lipoprotein cholesterol levels, lowering triglyceride levels, and effects on glucose metabolism and myocardial function. It remains unclear whether these differences significantly impact clinical outcomes or if 1 statin should be preferred over another. This review summarizes the properties of the 2 most potent statins available (atorvastatin and rosuvastatin), as well as assesses the comparative experimental and clinical trials that have been conducted on these 2 agents. We believe that the available body of evidence indicates that atorvastatin may have several advantages over rosuvastatin, despite the latter's greater potency, suggesting that atorvastatin should be the potent statin of choice, especially in treating patients with renal impairment or heart failure with concomitant coronary artery disease. The recent availability of atorvastatin as a generic option gives this drug another practical and compelling advantage over rosuvastatin.
Keyword Atorvastatin
Rosuvastatin
Chronic Kidney Disease (ckd)
Heart failure
Statins
Cholesterol
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 28 Apr 2013, 00:27:24 EST by System User on behalf of School of Medicine